Top Story Today
Lilly's Triple-Hormone Shot Just Posted Weight Loss Numbers That Rival Surgery
Eli Lilly's retatrutide, the first obesity drug to target three gut hormone receptors simultaneously, delivered 28.3% body weight loss over 80 weeks in Phase 3, with a subset of patients approaching 30% at two years and still losing. Those numbers used to require a surgeon and a permanently rearranged stomach. For context: Lilly's own Zepbound hits about 21%, and Novo Nordisk's best next-gen candidate managed 22.7%. Retatrutide isn't just leading the pack; it's rewriting what a weekly injection can do.
Why it matters: By adding a glucagon receptor to the GLP-1/GIP formula, Lilly now has a three-tiered obesity arsenal (oral, dual-agonist, triple-agonist) that no competitor can match, widening its lead over Novo Nordisk in the most lucrative drug race in a generation.
Read more →Deals, M&A, and Financings
Google's AI Drug Lab Just Raised More Than Most Biotechs Are Worth
Isomorphic Labs, the DeepMind spinoff that turned a Nobel Prize in protein folding into a drug discovery platform, closed a $2.1 billion Series B, doubling the previous record for AI drug discovery financing. The company has $3 billion in pharma deals with Lilly and Novartis but zero drugs in humans. First clinical trials are targeted for late 2026.
Read more →Lilly Paid $202M for a Startup With Zero Products. The Reason? Gene Therapy's Hardest Problem.
Eli Lilly acquired Engage Biologics, a Y Combinator alum with no revenue or clinical data, for up to $202 million. The prize: a lipid nanoparticle platform called Tethosome that could deliver DNA to cell nuclei without a virus, solving the bottleneck that has constrained gene therapy for decades. It's the latest piece in Lilly's genetic medicines shopping spree.
Read more →A Preclinical Biotech Bought Another Preclinical Biotech for $320M. Yes, Really.
Liminatus Pharma agreed to acquire AI-driven CAR-T startup InnocsAI in an all-stock deal valued at $320 million. The science (AI-designed, logic-gated CAR-T cells for solid tumors) is genuinely interesting. The structure, with massive dilution, related-party ties, and two companies with zero clinical data combining, is raising eyebrows.
Read more →The $80M Bet That Superbugs Will Make Antibiotics Cool Again
Suzhou-based TenNor Therapeutics raised roughly $80 million in a Hong Kong IPO, a rare win for anti-infectives. Its lead drug, a hybrid molecule attacking H. pylori from two angles at once, beat the standard four-drug regimen in Phase III with a simpler three-drug combo. An NDA is under review in China, and the FDA granted Fast Track status.
Read more →Clinical and Regulatory
Merck's Crown Jewel Just Got a Turbocharger From China
A Chinese-made antibody-drug conjugate paired with Keytruda cut the risk of lung cancer progression by 65% in a Phase 3 trial. Median progression-free survival for the combo group hasn't even been reached yet. For Merck, facing a $29.5 billion patent cliff in 2028, it's exactly the lifeboat it needed.
Read more →A Billion-Dollar Parkinson's Drug Hit Every Target and Helped Nobody
Biogen and Denali's LRRK2 inhibitor achieved over 90% target engagement in a 650-patient Parkinson's trial, then missed every single clinical endpoint. The drug did exactly what the biology predicted; patients just didn't get better. The failure torpedoes the centerpiece of a partnership worth roughly $1 billion upfront and up to $2.5 billion total including milestones, and extends neuroscience's most heartbreaking pattern.
Read more →Leqembi's Skip-the-IV Version Just Hit a Three-Month FDA Delay
The FDA pushed its decision on subcutaneous Leqembi (the version that lets Alzheimer's patients skip 39 IV infusions entirely) from May to August 2026. The delay is procedural, not a safety concern, but it stings for a drug whose biggest commercial barrier isn't the science; it's getting elderly patients to show up at infusion centers twice a month.
Read more →Wild Cards
A Blood Test That Knows If It's Schizophrenia or Bipolar Disorder
The FDA granted Breakthrough Device Designation to a blood test from tiny Laguna Diagnostics that claims 98.3% accuracy in distinguishing schizophrenia from bipolar I disorder using mRNA expression patterns from 18 genes. For a field where misdiagnosis rates hit 70% and correct diagnosis can take a decade, even an adjunct tool this accurate could be transformative.
Read more →You Can Now Bet Real Money on Whether a Drug Trial Will Work
Prediction markets are letting people wager on clinical trial outcomes and FDA decisions, with platforms like Kalshi and a biotech-focused experimental platform called Endpoint Arena offering contracts. The promise: cleaner probability signals than noisy stock prices. The nightmare: a world where trial investigators can bet on their own results. Regulators are already circling.
Read more →